Glipden-Mv2

Description

GLIPDEN-MV2 contains Glimepiride 2 mg, Metformin Hydrochloride (SR) 500 mg and Voglibose 0.2 mg in tablet form. This three-drug combination brings together medicines with complementary glucose-lowering actions. Glimepiride stimulates insulin release, Metformin helps reduce glucose production by the liver and improves insulin sensitivity, while Voglibose slows the digestion and absorption of carbohydrates in the intestine. Together, these medicines may help improve glycaemic control in adults with type 2 diabetes mellitus when prescribed as part of an individualized treatment plan.

For related diabetic and cardiovascular formulations, explore the Cardries Biotic range from Medhexa Pharma for pharmaceutical products and business enquiries.

Therapeutic Segment

Anti-Diabetic Therapy | Type 2 Diabetes Management | Sulfonylureas | Biguanides | Alpha-Glucosidase Inhibitors | Glycemic Control

Uses of GLIPDEN-MV2

GLIPDEN-MV2 may be prescribed for the management of type 2 diabetes mellitus when combination oral therapy is considered appropriate.

Depending on the patient’s treatment plan, it may be used for:

• Type 2 diabetes mellitus
• Inadequate glycaemic control with lifestyle measures and previous therapy
• Patients requiring more than one oral glucose-lowering medicine
• Supporting both fasting and post-meal blood glucose control
• Long-term blood glucose management as part of an individualized diabetes-care plan

Glimepiride, Metformin and Voglibose work through different mechanisms. Therefore, their combination can provide broader glucose-lowering activity than a single medicine. The choice of combination should depend on the patient’s blood glucose levels, kidney and liver function, risk of hypoglycaemia and other clinical factors.

Key Benefits of GLIPDEN-MV2

• Supports Blood Sugar Control: Helps lower elevated blood glucose levels in adults with type 2 diabetes.
• Three-Way Glucose-Lowering Action: Combines Glimepiride, Metformin SR and Voglibose.
• Supports Insulin Action: Metformin improves insulin sensitivity and helps reduce hepatic glucose production.
• Supports Insulin Release: Glimepiride stimulates insulin secretion from pancreatic beta cells.
• Helps Manage Post-Meal Glucose: Voglibose slows carbohydrate digestion and absorption, helping reduce post-meal glucose rises.
• Convenient Combination: Provides three oral antidiabetic medicines in a single tablet.

How GLIPDEN-MV2 Works

Glimepiride belongs to the sulfonylurea class. It stimulates the pancreatic beta cells to release insulin, which helps lower blood glucose. Sulfonylureas, including glimepiride, can cause hypoglycaemia and require appropriate dose selection and monitoring.

Metformin Hydrochloride SR belongs to the biguanide class. It primarily reduces glucose production by the liver and also improves insulin sensitivity, allowing the body to use glucose more effectively. Metformin remains a commonly used foundation of type 2 diabetes treatment when appropriate.

Voglibose is an alpha-glucosidase inhibitor. It delays the breakdown and absorption of carbohydrates in the intestine, which can help reduce the rise in blood glucose after meals. Indian diabetes guidance recognizes alpha-glucosidase inhibitors such as voglibose as oral glucose-lowering medicines used in appropriate patients.

Common Side Effects of GLIPDEN-MV2

Possible side effects may include:

• Nausea
• Diarrhoea
• Abdominal discomfort
• Bloating
• Flatulence
• Loss of appetite
• Indigestion
• Headache
• Dizziness
• Low blood sugar or hypoglycaemia

Gastrointestinal effects are commonly associated with Metformin and Voglibose. Because GLIPDEN-MV2 contains Glimepiride, hypoglycaemia is an important safety consideration, particularly when meals are missed, physical activity increases or the dose is higher than required.

Important Safety Information

Use GLIPDEN-MV2 only under the direction of a qualified healthcare professional.

• Monitor blood glucose regularly according to your diabetes-care plan.
• Glimepiride can cause hypoglycaemia. Learn to recognize symptoms such as sweating, shakiness, hunger, dizziness, confusion or weakness.
• Do not skip meals after taking a medicine containing Glimepiride unless your healthcare professional specifically advises otherwise.
• Tell your doctor if you have kidney or liver disease, because the suitability and dosage of these medicines may require adjustment.
• Metformin should not be used in patients with severe renal impairment. Current diabetes guidance recommends avoiding Metformin when eGFR is below 30 mL/min/1.73 m².
• Metformin can rarely cause lactic acidosis, particularly in situations involving significant renal impairment or other risk factors. Seek urgent medical attention for severe weakness, unusual sleepiness, breathing difficulty or other serious symptoms.
• Voglibose can cause gastrointestinal symptoms because it changes carbohydrate digestion and absorption.
• Tell your healthcare professional about all prescription medicines, supplements and herbal products you use, as other medicines can affect blood glucose or increase the risk of hypoglycaemia.
• Discuss the medicine with your doctor before surgery or procedures that may affect your food intake or diabetes treatment.
• Avoid excessive alcohol consumption because it can affect blood glucose control and may increase the risks associated with Metformin.
• Do not stop or change the dose without medical advice.
• Maintain the diet, physical activity and blood glucose-monitoring plan recommended by your healthcare professional.

For additional information about diabetes medicines and glucose-lowering treatment, refer to the American Diabetes Association Standards of Care.

Dosage & Administration

Take GLIPDEN-MV2 exactly as prescribed by your healthcare professional.

The appropriate dose and timing depend on the patient’s blood glucose levels, diabetes treatment history, kidney function, diet and response to therapy. Because the formulation contains Metformin SR, the tablet should be taken according to the specific instructions provided with the product.

Do not crush or chew the tablet if the approved product information specifies that it should be swallowed whole because of its sustained-release formulation.

Take the medicine with meals or at the timing specified by your healthcare professional. Regular meals are particularly important when using Glimepiride because skipping meals can increase the risk of hypoglycaemia.

Do not take an extra dose if you miss a dose unless specifically instructed by your healthcare professional.

Storage

• Store GLIPDEN-MV2 in a cool, dry place.
• Protect the tablets from excessive heat and moisture.
• Keep the tablets in their original BLISTER packaging until use.
• Protect from direct sunlight.
• Keep out of the sight and reach of children.
• Do not use the medicine after the expiry date printed on the pack.